Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 18/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11544791 | 0.86 | ALDH1A1 (0.53) | ACACBALDH1A1NPC1 | |
| SCHEMBL17845127 | 0.84 | APP (0.57) | ACACBNPC1 | |
| SCHEMBL27914449 | 0.82 | FFAR1 (0.56) | ACACBALDH1A1NPC1 | |
| SCHEMBL15184913 | 0.81 | PARP10 (0.58) | ACACBALDH1A1NPC1 | |
| SCHEMBL16367839 | 0.81 | ACACB (0.49) | ACACBALDH1A1NPC1 | |
| SCHEMBL27964813 | 0.80 | NPC1 (0.54) | ALDH1A1NPC1 | |
| SCHEMBL9202331 | 0.80 | FFAR1 (0.62) | ALDH1A1NPC1 | |
| SCHEMBL6834747 | 0.78 | APP (0.52) | ALDH1A1NPC1 | |
| SCHEMBL11902648 | 0.78 | GABRP (0.49) | ACACBALDH1A1NPC1 | |
| SCHEMBL852558 | 0.78 | APP (0.51) | ACACBALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453004-B2 | Formylated xanthocillin analogues as neuroprotective agents | NEURON BIOPHARMA, S.A. (ES) | 2016-09-27 | — | — | US | disclosed |
| US-20150011621-A1 | FORMYLATED XANTHOCILLIN ANALOGUES AS NEUROPROTECTIVE AGENTS | NEURON BIOPHARMA, S.A. (ES) | 2015-01-08 | — | — | US | disclosed |
| WO-2013117789-A2 | FORMULATED XANTHOXYLINE ANALOGUES AS NEUROPROTECTORS | NEURON BIOPHARMA, S.A. (ES) | 2013-08-15 | — | — | WO | disclosed |
| US-20070270428-A1 | Use of Cyclooxygenase-2 Inhibitors for the Treatment of Depressive Disorders | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | disclosed |
| US-20070142411-A1 | Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| EP-1687001-A2 | USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-08-09 | — | — | EP | disclosed |
| EP-1510519-B1 | Pharmaceutical compositions comprising 2,3-diarylpyrazolo[1,5-B]pyridazine derivatives | GLAXO GROUP LTD (GB) | 2006-02-15 | — | — | EP | disclosed |
| WO-2005049034-A2 | USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| US-20050113377-A1 | 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase, 2 (COX-2) inhibitors | BESWICK PAUL J (GB) | 2005-05-26 | — | — | US | disclosed |
| EP-1510519-A1 | Pharmaceutical compositions comprising 2,3-diarylpyrazolo[1,5-B]pyridazine derivatives | GLAXO GROUP LIMITED (GB) | 2005-03-02 | — | — | EP | disclosed |
| US-6861429-B2 | 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-01 | — | — | US | disclosed |
| US-6831097-B2 | For therapy of pain, fever, inflammation of a variety of conditions and diseases | SMITHKLINE BEECHAM CORPORATION | 2004-12-14 | — | — | US | disclosed |
| EP-1369421-B1 | Pharmaceutical compositions comprising 2,3-Diaryl-pyrazolo[1,5-B]pyridazine derivatives | GLAXO GROUP LTD (GB) | 2004-11-03 | — | — | EP | disclosed |
| EP-1369421-A1 | Pharmaceutical compositions comprising 2,3-Diaryl-pyrazolo[1,5-B]pyridazine derivatives | GLAXO GROUP LIMITED (GB) | 2003-12-10 | — | — | EP | disclosed |
| EP-1032575-B1 | 2,3-DIARYL-PYRAZOLO(1,5-B)PYRIDAZINES DERIVATIVES, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | GLAXO GROUP LTD (GB) | 2003-07-23 | — | — | EP | disclosed |
| US-20030040517-A1 | 2,3-Diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibirors | SMITHKLINE BEECHAM CORPORATION | 2003-02-27 | — | — | US | disclosed |
| US-20030008872-A1 | 2,3-Diaryl-pyrazolo[1,5-B]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors | BESWICK PAUL JOHN (GB) | 2003-01-09 | — | — | US | disclosed |
| US-6451794-B1 | 2,3-Diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2(COX-2) inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-09-17 | — | — | US | disclosed |
| EP-1032575-A1 | 2,3-DIARYL-PYRAZOLO(1,5-B)PYRIDAZINES DERIVATIVES, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999012930-A1 | 2,3-DIARYL-PYRAZOLO[1,5-B]PYRIDAZINES DERIVATIVES, THEIR PREPA RATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270428-A1 | Use of Cyclooxygenase-2 Inhibitors for the Treatment of Depressive Disorders | TPH2, PTGS2, PTGES2 | ACACB 784/4885ALDH1A1 396/4885NPC1 3775/4885 |
| US-20050113377-A1 | 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase, 2 (COX-2) inhibitors | PTGER1, NCOA1, NCOR2 | ACACB 1378/4885ALDH1A1 983/4885NPC1 776/4885 |
| US-20030008872-A1 | 2,3-Diaryl-pyrazolo[1,5-B]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors | PTGS1, CBR1, PTGER1 | ACACB 1083/4885ALDH1A1 645/4885NPC1 399/4885 |
| US-20030040517-A1 | 2,3-Diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibirors | CBR1, CRHR1, CRHR2 | ACACB 1166/4885ALDH1A1 1038/4885NPC1 1073/4885 |
| US-20150011621-A1 | FORMYLATED XANTHOCILLIN ANALOGUES AS NEUROPROTECTIVE AGENTS | FPR1, FPR2, FPR3 | ACACB 4072/4885ALDH1A1 4607/4885NPC1 2951/4885 |
| US-20070142411-A1 | Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders | PTGES2, PTGER2, PTGDR2 | ACACB 2262/4885ALDH1A1 112/4885NPC1 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.